Literature DB >> 32811601

Relationship of Preoperative Serum Uric Acid Level with Survival in Colorectal Cancer.

Mehmet Akif Üstüner1, Lütfi Dogan2.   

Abstract

OBJECTIVE: To investigate the prognostic significance of uric acid level in colorectal cancer in addition to conventional factors in terms of  survival. STUDY
DESIGN: Observational Study. PLACE AND DURATION OF STUDY: At the University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey, between January 2012 and December 2019.   Methodology: A total of selected 332 patients, who underwent surgery for colorectal cancer between 2012 and 2019, were retrospectively reviewed. Patients with a history of neoadjuvant therapy due to rectal cancer, GUT disease, renal failure, stage 4 disease, emergency surgery and severe preoperative infection, were excluded from the study. Peripheral blood samples were collected about a week before the operation. Serum uric acid (SUA) values were measured and recorded.  
Results: The patients comprised 198 males and 134 females with a mean age  62.2 ±11.7 years (14-91) years in total. Conventional surgery was performed in 228 patients, and laparoscopy in 104 patients. Uric acid level, number of pathological lymph nodes, number of pathological lymph nodes/total number of lymph nodes (LNO), perineural invasion, type of surgery and disease stage were found to be factors affecting the prognosis (p <0.05). Uric acid cut off value of 5.3 or higher was found to be statistically significant in terms of survival.
CONCLUSION: Serum uric acid (SUA) value measured preoperatively was found to be a prognostic factor for colorectal cancer. Key Words: Serum uric acid (SUA), Colon cancer, Rectal cancer, Prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32811601     DOI: 10.29271/jcpsp.2020.07.717

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  3 in total

1.  Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX.

Authors:  Xi Zhang; Qing-Hong Chen; Ying Yang; Jing-Xin Lin; Yan-Chun Li; Tian-Yu Zhong; Jie Chen; Si-Qi Wu; Xiao-Hu Chen; Rui-Si Zhou; Jia-Man Lin; Dong-Qing Wang; Qiu-Xing He; Yan-Ting You; Xing-Hong Zhou; Qiang Zuo; Yan-Yan Liu; Jing-Ru Cheng; Yi-Fen Wu; Xiao-Shan Zhao
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

2.  An exploratory study on TCM syndrome differentiation in preoperative patients with colorectal cancer assisted by laboratory indicators.

Authors:  Ya-Nan Wang; Min Zou; Dou Wang; Zhi-Kuan Zhang; Lian-Ping Qu; Jing Xu; Cai-Dong Shi; Feng Gao
Journal:  Heliyon       Date:  2022-08-14

Review 3.  Role of Natural Antioxidant Products in Colorectal Cancer Disease: A Focus on a Natural Compound Derived from Prunus spinosa, Trigno Ecotype.

Authors:  Maria Condello; Stefania Meschini
Journal:  Cells       Date:  2021-11-26       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.